Biomarkers May Identify Risk for Preeclampsia in Lupus Pregnancies

Measuring levels of circulating antiangiogenic factors—soluble fms-like tyrosine kinase 1 (sFlt 1) and soluble endoglin (sEng)—may help identify which patients with systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APLA) will develop preeclampsia. The researchers suggest that an angiogenic imbalance early in pregnancy increases the vulnerability to triggers of preeclampsia, according to data from the PROMISSE Study (Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic lupus Erythematosus) presented at the American College of Rheumatology meeting in Boston.

Read full article